MRK vs UTHR
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. UTHR: United Therapeutics is a biotechnology company dedicated to providing innovative, life-extending therapies for patients with pulmonary arterial hypertension and other rare diseases through a focus on proprietary treprostinil-based treatments.
Side-by-side fundamentals
| Metric | MRK | UTHR | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $128.37 | $532.94 | |
| Market cap as of 2026-08-08 | $317.1B | $22.9B | |
| P/E as of 2026-08-08 | 99.36 | 17.69 | UTHR lower |
| PEG as of 2026-08-08 | 4.91 | 2.03 | UTHR lower |
| Net margin as of 2026-08-08 | +4.8% | +40.6% | UTHR higher |
| Gross margin as of 2026-08-08 | +77.3% | +86.6% | UTHR higher |
| Operating margin as of 2026-08-08 | +9.6% | +45.3% | UTHR higher |
| ROE as of 2026-08-08 | +17.9% | +19.2% | UTHR higher |
| ROA as of 2026-08-08 | +7.0% | +17.3% | UTHR higher |
| Debt / equity as of 2026-08-08 | 1.07 | 0.00 | UTHR lower |
| Revenue growth (YoY) as of 2026-08-08 | +4.6% | +5.9% | UTHR higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +18.0% | UTHR higher |
| Dividend yield as of 2026-08-08 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-08 | 0.20 | 0.50 | |
| 1-year return as of 2026-08-06 close | +61.6% | +76.2% | UTHR higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.